Chairs: Amir Kalali MD, Jill Rasmussen MD
Despite the emergence of new classes of antidepressants, the management of depression continues to be challenging with remission rates remaining around 33%.
A number of studies have used new strategies in partial and non-responders, as well as treatment resistant patients. This session will review and critically appraise the lessons learned from these studies. Questions will be posed about the current concepts of early onset of response, partial response and treatment resistance and whether these should be refined. Similarities and differences in regulatory thinking about clinical trial methodology and potential labelling will be explored and the potential relevance of these methodologies to inform other therapeutic areas will be discussed.